Skip to content
Menu

RBC Capital Maintains Outperform on ResMed, Raises Price Target to $288

Benzinga Newsdesk 3 weeks ago

Analyst RatingsNewsPrice Target

This page contains a summary, not the full article. Continue to benzinga.com to read the original report.

RBC Capital analyst Craig Wong-Pan maintains ResMed (NYSE:RMD) with a Outperform and raises the price target from $262 to $288.

RBC Capital analyst Craig Wong-Pan maintains ResMed (NYSE:RMD) with a Outperform and raises the price target from $262 to $288.

Read at benzinga.com

← All stock news